bluuebunny/crossref_metadata_2025_split huggingface dataset:
Cannabis use, comorbidities, and prescription medication use among older adults in a large healthcare system in Los Angeles, CA 2019–2020
Authors: Javanbakht Marjan , Takada Sae , Akabike Whitney , Shoptaw Steve , Gelberg Lillian 
Published: March 2022

AbstractObjectiveTo describe the reported prevalence of cannabis use and co‐use with prescription medications among older adult patients attending primary care (PC) clinics in Los Angeles, CA.MethodsWe used electronic health record (EHR) data from sixty PC clinics part of a university‐based, urban healthcare system. Patients' ≥50 years of age with an annual physical examination between July 2019 and May 2020 were eligible for inclusion (n = 42,555). Cannabis use was assessed by clinic staff at the time of the visit and recorded in the EHR. We also used EHR data on clinical characteristics including current prescriptions and comorbidities.ResultsThe median age was 63 years (range: 50–101) and 56% were female. Recent cannabis use was reported by 7.6%, which was higher than tobacco use (4.0%; p < 0.01). Prevalence of cannabis use was higher among patients prescribed psychotropic medications. For instance, 10.9% of patients prescribed benzodiazepines reported cannabis use as compared with 7.3% among patients without a prescription for benzodiazepines (p < 0.01). Patients with neurologic/musculoskeletal medications such as antiepileptics also had a higher prevalence of cannabis use when compared with those without these prescriptions (13.6% vs. 7.6% respectively; p < 0.01) as did those who were prescribed muscle relaxants (10.3% vs. 7.5% respectively; p < 0.01). After adjusting for age, sex, race/ethnicity, and comorbidities those prescribed medications for psychiatric (adjusted OR = 1.5; 95% CI 1.4–1.7), respiratory (adjusted OR = 1.2; 95% CI 1.1–1.3), or neurologic conditions (adjusted OR = 1.4; 95% CI 1.2–1.5) had increased odds of cannabis use compared with those not prescribed these medications.DiscussionThe prevalence of cannabis use among older adults attending PC clinics in a university‐based healthcare system was higher among those prescribed medications, which may interact with cannabis. These findings suggest that key groups of older patients who may benefit from routine PC screening for cannabis use and brief advice.
“You can't make me do it!” A model of consumer compliance
Authors: Bharti Vijay Payal , Gratz Elizabeth T. , Fitzgerald M. Paula 
Published: March 2022

AbstractConsumer well‐being often depends on compliance with service setting rules and product/service use guidelines. This issue came to the forefront during the COVID‐19 pandemic. Here, we propose and test a compliance model in the context of COVID‐19 social distancing guidelines. Although COVID mitigation is politicized, we fully mediate the impact of political ideology with three constructs: (1) consumer perception that freedom is restricted, (2) complacency, and (3) perceived ethicality. We suggest specific tools that help bypass the political polarization that has occurred in the pandemic. The model can be applied to other areas in which compliance is key to consumer well‐being, such as enforcing age‐related restrictions on purchases and safety‐related behaviors.
LncRNA Opa interacting protein 5‐antisense RNA 1 (OIP5‐AS1) promotes the migration, invasion and epithelial‐mesenchymal transition (EMT) through targeting miR‐147a/insulin‐like growth factor 1 receptor (IGF1R) pathway in cervical cancer tissues and cell model
Authors: Zhang Limei , Cai Yufei , Tian Chenchen , Li Yanru , Ma Kuili , Gao Xiaolei , Liu Lili , Jiang Yan , Wen Wanting , Ma Zhe 
Published: March 2022

AbstractBackgroundTwo factors involved in regulation, long noncoding RNA Opa interacting protein 5‐antisense RNA 1 (lncRNA OIP5‐AS1) and microRNA‐147a, were found in cervical cancer. Therefore, the investigation of the specific regulation of miR‐147a by OIP5‐AS1 was performed in cervical cancer.MethodThe cervical cancer tissues were collected from patients with cervical cancer (n = 50). The expression of OIP5‐AS1, miR‐147a, proteins in epithelial‐mesenchymal transition (EMT) process and insulin‐like growth factor 1 receptor (IGF1R) were measured by quantitative real‐time polymerase chain reaction (qRT‐PCT) or western blotting. Cell motility and the relationship between OIP5‐AS1 and miR‐147a were detected or analyzed by wound healing test, Transwell assay, dual‐luciferase reporter assay, RNA binding protein immunoprecipitation assay or Pearson correlation in OIP5‐AS1, or miR‐147a over‐expressed and/or suppressed cervical cancer cells.ResultsOIP5‐AS1 showed the high‐expression and miR‐147a showed the low‐expression in tumor tissues collected from patients with cervical cancer and cell lines Hela, CaSki, Siha, and ME‐180. The low‐expression of OIP5‐AS1 suppressed the motility of Caski cells, as well as up‐regulated the level of E‐cadherin, which a key protein in EMT. There were targeting sites between miR‐147a and OIP5‐AS1. OIP5‐AS1 induced the down‐regulation of miR‐147a, so miR‐147a was inversely correlated with OIP5‐AS1. The down‐regulation of miR‐147a increased IGF1R and E‐cadherin, and these increases were alleviated by OIP5‐AS1 knockdown.ConclusionLncRNA OIP5‐AS1 promotes the migration, invasion and EMT of cervical cancer cells via targeting miR‐147a/IGF1R pathway.
The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast
Authors: Arias de la Rosa Ivan , López‐Montilla Maria Dolores , Román‐Rodríguez Cristobal , Pérez‐Sánchez Carlos , Gómez‐García Ignacio , López‐Medina Clementina , Ladehesa‐Pineda Maria Lourdes , Ábalos‐Aguilera Maria del Carmen , Ruiz Desiree , Patiño‐Trives Alejandra Maria , Luque‐Tévar Maria , Añón‐Oñate Isabel , Pérez‐Galán Maria Jose , Guzmán‐Ruiz Rocio , Malagón Maria M. , López‐Pedrera Chary , Escudero‐Contreras Alejandro , Collantes‐Estévez Eduardo , Barbarroja Nuria 
Published: March 2022

AbstractObjectives(1) To evaluate clinical and molecular cardiovascular disease (CVD) signs and their relationship with psoriatic arthritis (PsA) features and (2) to identify a clinical patient profile susceptible to benefit from methotrexate (MTX) and/or apremilast regarding CVD risk.MethodsThis cross‐sectional study included 100 patients with PsA and 100 age‐matched healthy donors. In addition, an exploratory cohort of 45 biologically naïve patients treated for 6 months with apremilast, MTX or combined therapy according to routine clinical practice was recruited. Extensive clinical and metabolic profiles were obtained. Ninety‐nine surrogate CVD‐related molecules were analysed in plasma and peripheral blood mononuclear cells (PBMCs). Hard cluster analysis was performed to identify the clinical and molecular phenotypes. Mechanistic studies were performed on adipocytes.ResultsCardiometabolic comorbidities were associated with disease activity and long‐term inflammatory status. Thirty‐five CVD‐related proteins were altered in the plasma and PBMCs of PsA patients and were associated with the key clinical features of the disease. Plasma levels of some of the CVD‐related molecules might distinguish insulin‐resistant patients (MMP‐3, CD163, FABP‐4), high disease activity (GAL‐3 and FABP‐4) and poor therapy outcomes (CD‐163, LTBR and CNTN‐1). Hard cluster analysis identified two phenotypes of patients according to the rates of cardiometabolic comorbidities with distinctive clinical and molecular responses to each treatment.Conclusions(1) Novel CVD‐related proteins associated with clinical features could be emerging therapeutic targets in the context of PsA and (2) the pleiotropic action of apremilast could make it an excellent choice for the management of PsA patients with high CVD risk, targeting metabolic alterations and CVD‐related molecules.
Negotiating the mainstream: Proximate stancetaking and far‐right policy proposals in Bundestag debates
Authors: Sterphone J 
Published: March 2022

AbstractDuring talk, parliamentarians (re)negotiate the boundaries of mainstream and marginal politics. With far‐right parties in parliament(s) in force, center‐right parties—especially those that have coopted far‐right stances—must establish and maintain their position within the political mainstream, while ostracizing and marginalizing neighboring positions from the far‐right. Drawing on video data of policy debates in the German Bundestag, this paper takes a conversation analytic approach to examining practices deployed by members of mainstream parties for rejecting proposals made by the far‐right. It shows ways center‐right politicians (re)produce both the mainstream and their own political identity by rejecting such proposals without also rejecting outright the underlying stance. By distinguishing between oppositional and proximate stancetaking, this analysis further demonstrates ways that politicians orient to stancetaking as structuring rejection formats.
Transgression in institutional space: Heteroglossic political signs in a Hong Kong university
Authors: Huang Corey Fanglei 
Published: March 2022

AbstractThis article studies the sociolinguistic and social semiotic transgression enacted by a group of political signs in a public university in Hong Kong. It demonstrates how the signs break normative/stabilized social, cultural and political boundaries and order by mixing up multifarious stylistic and generic resources, resulting in aheteroglossicblending of diverse, often incongruent identities, voices and ideologies predominantly rooted in the modern history of Greater China. The article suggests that this heteroglossia ideologically distances the university away from the state, defends its historical, Western‐style autonomy and aligns it with the local pro‐democracy civil society amid the escalating sociopolitical tensions in Hong Kong particularly after the Umbrella Movement in 2014. It shows the value of linguistic and semiotic landscape research on institutions as dynamic and complex communities and discursive spaces.
Association between serum miRNAs and gingival gene expression in an obese rat model
Authors: Maruyama Takayuki , Kobayashi Terumasa , Sugiura Yoshio , Yoneda Toshiki , Ekuni Daisuke , Morita Manabu 
Published: March 2022

AbstractIntroductionRecent studies have reported a relationship between periodontitis and obesity; however, the mechanisms of obesity’s effects on periodontitis are not well understood. On the other hand, microRNAs (miRNAs) are known to play key roles in the post‐transcriptional regulation gene expression by suppressing translation and protein synthesis. We examined the association between obesity‐related miRNAs and gene expression in gingival tissue using miRNA–messenger RNA (mRNA) pairing analysis in an obese rat model.MethodsSixteen male Wistar rats aged 8 weeks old were divided into two groups: the control group was fed a normal powdered food for 8 weeks, and the obesity group was fed a high‐fat diet for 8 weeks. Distance from the cement–enamel junction to the alveolar bone crest of the first molars was measured. miRNA microarray analysis was performed on samples of serum and gingival tissue; the resulting data were used to calculate fold changes in miRNA levels in the obesity group relative to the control group, and miRNA–mRNA pairing analysis was performed to identify mRNAs potentially targeted by miRNAs of interest.ResultsAlveolar bone loss in the obesity group exceeded that in the control group (p = .017). miRNA–mRNA pairing analysis identified an association between 4 miRNAs (miR‐759, miR‐9a‐3p, miR‐203b‐3p, and miR‐878) that were differentially expressed in the obesity and control groups and 7 genes (Ly86, Arid5b, Rgs18, Mlana, P2ry13, Kif1b, and Myt1) expressed in gingival tissue.ConclusionThis study revealed that several miRNAs play an important role in the mechanism of periodontal disease progression induced by the obesity.
Prediction of vascular invasion using a 7‐point scale computed tomography grading system in adrenal tumors in dogs
Authors: Pey Pascaline , Specchi Swan , Rossi Federica , Diana Alessia , Drudi Ignazio , Zwingenberger Allison L. , Mayhew Philipp D. , Pisoni Luciano , Mari Daniele , Massari Federico , Dalpozzo Boris , Fracassi Federico , Nicoli Stefano 
Published: March 2022

AbstractBackgroundPrevious studies evaluating the accuracy of computed tomography (CT) in detecting caudal vena cava (CVC) invasion by adrenal tumors (AT) used a binary system and did not evaluate for other vessels.ObjectiveTest a 7‐point scale CT grading system for accuracy in predicting vascular invasion and for repeatability among radiologists. Build a decision tree based on CT criteria to predict tumor type.MethodsRetrospective observational cross‐sectional case study. Abdominal CT studies were analyzed by 3 radiologists using a 7‐point CT grading scale for vascular invasion and by 1 radiologist for CT features of AT.AnimalsDogs with AT that underwent adrenalectomy and had pre‐ and postcontrast CT.ResultsNinety‐one dogs; 45 adrenocortical carcinomas (50%), 36 pheochromocytomas (40%), 9 adrenocortical adenomas (10%) and 1 unknown tumor. Carcinoma and pheochromocytoma differed in pre‐ and postcontrast attenuation, contralateral adrenal size, tumor thrombus short‐ and long‐axis, and tumor and thrombus mineralization. A decision tree was built based on these differences. Adenoma and malignant tumors differed in contour irregularity. Probability of vascular invasion was dependent on CT grading scale, and a large equivocal zone existed between 3 and 6 scores, lowering CT accuracy to detect vascular invasion. Radiologists' agreement for detecting abnormalities (evaluated by chance‐corrected weighted kappa statistics) was excellent for CVC and good to moderate for other vessels. The quality of postcontrast CT study had a negative impact on radiologists' performance and agreement.Conclusions and Clinical ImportanceFeatures of CT may help radiologists predict AT type and provide probabilistic information on vascular invasion.
Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review
Authors: Babar Mustufa , Loloi Justin , Tang Kevin , Syed Umar , Ciatto Michael 
Published: March 2022

AbstractWater vapor thermal therapy (Rezum) is a novel, minimally invasive surgical technology used to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The objective of this systematic review is to evaluate the latest efficacy and safety profile of Rezum in patients with LUTS secondary to BPH. PubMed/MEDLINE and the Cochrane Library databases were systematically searched, in accordance with the PRISMA statement, for relevant articles in the English language till 1 August 2021. Randomized and nonrandomized studies that evaluated urinary outcomes and/or adverse events were deemed eligible. Nineteen studies (N = 1942), published in 25 articles, were included. International Prostate Symptom Score (IPSS), quality of life (QoL), and maximum urinary flow rate (Qmax) significantly improved as early as 1 month postoperatively and remained durable for up to 5 years. Significant median percent improvements in IPSS, QoL, and Qmax at 3 months were 51%, 51%, and 66%, respectively. Patients with obstructive median lobes, large prostates (>80 g), small prostates (<30 g), and urinary retention also experienced significant relief in LUTS, with 83% of urinary retention patients becoming catheter independent at a median of 14 days. Most adverse events were transient and nonserious and occurred in 0% to 76% of patients (median 29%), with de novo erectile dysfunction rates ranging between 0% and 3.1%. Surgical retreatment rate ranged between 4.4% and 7.5% at 5 years postoperatively. Rezum provides durable improvements in symptoms, irrespective of prostate volume and urinary retention status, and has low rates of sexual dysfunction.
Family‐centred care change during COVID‐19
Authors: Vetcho Siriporn , Cooke Marie , Petsky Helen , Saito Amornrat , Ullman Amanda J. 
Published: March 2022

AbstractBackgroundFamily‐centred care (FCC) is an approach to promote family and health care provider partnership. This has been incorporated into neonatal intensive care units (NICUs) worldwide. However, FCC in low resource health settings, such as Thailand, is challenging and further impacted by coronavirus disease 2019 (COVID‐19).AimsTo evaluate FCC innovations to improve respect, collaboration and support in a Thai NICU.Study designA quasi‐experimental study was conducted in an NICU in southern Thailand. Pre‐implementation was prior to COVID‐19, and parental and staff perceptions of FCC were measured via Perceptions of Family Centred Care‐Parent (PFCC‐P) and ‐Staff (PFCC‐S) survey. The FCC innovations were developed by stakeholders based on the COVID‐19 restrictions, pre‐survey results, parents' and clinicians' interviews and integrative review, then implemented via a flowchart. Post‐implementation evaluation was via repeated surveys. Comparisons were made pre‐and post‐implementation, with Mann–Whitney U‐test statistics for parents and Wilcoxon's Rank Sum for staff.ResultsA total of 185 (85 pre; 100 post) parents and 20 (pre and post; paired group) health care professionals participated. Because of COVID‐19, many planned interventions were unfeasible, however, other innovations achieved (e.g., structured telephone updates, information booklet revision). There was an increase in parents' perception of respect ([median] 2.50–3.50), collaboration (2.33–3.33) and support (2.60–3.60) domains and overall (2.50–3.43; p < .001; 95% CI: 2.93–3.11). Interdisciplinary professionals' perception of FCC did not significantly change pre‐and post‐implementation/COVID‐19 pandemic for respect (3.00–2.92), collaboration (3.22–3.33), support (3.20–3.20) and overall (3.15–3.20; 95% CI: 3.10–3.25).ConclusionDespite the challenges of COVID‐19 restricting NICU access, the provision of FCC was maintained and even improved.Relevance to clinical practiceFurther research is necessary to develop FCC practice innovations associated with communication, across diverse health care systems and resources.
Associations between child filaggrin mutations and maternal diet with the development of allergic diseases in children
Authors: Venter Carina , Palumbo Michaela P. , Sauder Katherine A. , Glueck Deborah H. , O’Mahony Liam , Yang Ivana , Davidson Elizabeth J. , Brough Helen A. , Holloway John W. , Fleischer David M. , Ben‐Abdallah Miriam , Dabelea Dana 
Published: March 2022

AbstractBackgroundFilaggrin (FLG) loss‐of‐function mutations in children and maternal diet in pregnancy have been implicated in child allergy outcomes. This paper studies the questions: “do FLG mutations modify the effect of maternal diet on the odds of development of allergic diseases?” and “which factor leads to the highest rate of diagnosis allergic diseases over time, maternal diet, or FLG mutations?”.MethodsExact logistic regressions studied effect modification. Cox proportional hazard models compared the rate of allergic disease development in three groups (N = 624): (1) children with FLG mutation, (2) children without FLG mutation whose mothers did not eat an allergy preventive diet, and (3) children without FLG mutation whose mothers ate an allergy preventive diet. Maternal diet was classified using a validated index.ResultsCox models showed the development of atopic dermatitis, asthma, and wheeze was significantly higher for children in group 1 versus 3 (HR = 2.40 [1.32, 4.37], HR = 2.29 [1.05, 4.97], and HR 2.10 [1.004, 4.38], respectively), but not significantly higher for children in group 1 versus 2 (HR = 1.30 [0.74, 2.29], HR = 1.27 [0.61, 2.63], and HR = 1.29 [0.65, 2.58], respectively). Development of allergic rhinitis was significantly higher for group 1 versus 2 and 3 (1 vs. 2: HR = 2.29 [1.10, 4.76]; 1 vs. 3: HR = 3.21 [1.46, 7.08]). There was no significant effect modification for any outcome.ConclusionChildren with FLG mutation had similar risk of atopic dermatitis, asthma, and wheeze as children without an FLG mutation whose mothers did not eat an allergy preventive diet during pregnancy. Child FLG mutation did not modify the effect of maternal diet. The results suggest that maternal diet in pregnancy, a modifiable risk factor, could be a target for preventive interventions.
Consistency of remifentanil concentrations in propofol–Remifentanil infusions. A laboratory‐based study
Authors: Wylie Nicole , Beale Lee , Westley Ian 
Published: March 2022

AbstractBackgroundThere is increasing interest in two‐agent single‐pump intravenous infusions for anesthesia and sedation in pediatric patients. Propofol–remifentanil is one such mixture.The poor miscibility of such admixtures when remifentanil is added in very high concentrations and when the admixtures are maintained in static conditions has been demonstrated; however, these physiochemical properties have not been examined in clinically relevant concentrations or settings.AimTo examine if propofol–remifentanil admixtures maintain consistent remifentanil delivery when mixed in clinically relevant remifentanil concentrations and subjected to the physical effects of an actively infusing, directly‐engaged syringe driver system with an extension line, as occurs when propofol–remifentanil is administered to a patient.MethodsA propofol 10 mg.ml−1 combined with remifentanil 5 mcg.ml−1 solution was run using a Paedfusor® propofol target‐controlled infusion model for 10 kg and 20 kg children for 57 min at a target plasma concentration of 3 mcg.ml−1 through a 30 ml syringe, 180 cm minimum volume extension line, lever lock cannula, interlink injection site, and 22 g intravenous cannula into sample pots. Samples were taken at the completion of the loading bolus, 1 and 2 min postcompletion of loading bolus, and every 5 min thereafter. The remifentanil concentration in these samples was then assayed using chromatography.ResultsThere was no difference in the concentration of remifentanil in the samples based on the duration of infusion to the endpoint of 1 h, or on the patient weight model used. The concentration remained 5 mcg.ml−1 +/− 0.5 mcg.ml−1 per sample. The measurement uncertainty for the assay at 0.5 mcg.ml−1 is +/− 0.2 mcg.ml−1.ConclusionThe concentration of remifentanil was 5 mcg.ml−1 +/− 0.5 mcg.ml−1 and was consistent across 57 min of infusion, and two different pediatric weight profiles.